Xience, diagnostics help fuel Abbott's Q1 sales growth

April 21, 2010 by MassDevice staff

Strong sales of Xience stents overseas and diagnostics tools back home contribute to Abbott's $7.7 billion in first-quarter revenues; net profit tops $1 billion, down 30 percent from 2009 levels.

ABT logo

Paced by strong international growth, coronary stent sales for Abbott (NYSE:ABT) rose 13 percent during the first three months of 2010, to $455 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.